Clinical trial · Observational
East Asian Breast Cancer Genome Atlas and Recurrence Risk Prediction
The Cancer Genome Atlas and Recurrence Risk Prediction of East Asian Breast Cancer: a Multicenter Collaborative Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This project aims to establish the cancer genome atlas and the platform of recurrence risk prediction specific for East Asian breast cancer patients. The study was planned to collect blood sample, fresh tumor tissue, and paraffin embedded tumor tissue from 2000 patients. Aims to identify unique genetic alterations in Asian tumors, to identify the susceptible genes for breast carcinogenesis in East Asia, and to establish the new platform for accurate prediction of recurrence. The investigator will explore the association of patient outcomes with the genetic alterations from the cancer atlas of East Asian breast tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PAM50 | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Prevalence of unique genetic alterations
- timeFrame
- 3 years
- description
- To establish the cancer genome atlas and identify the susceptible genes for breast carcinogenesis in East Asia
Secondary outcomes (1)
- measure
- Recurrence rate
- timeFrame
- 10 years
- description
- To establish the new platform for accurate prediction of recurrence
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * 1\. Aged more than 20-year-old at the time of informed consent. * 2\. An unconfirmed breast tumor, or have histologically confirmed invasive breast cancer. * 3\. Have radiological or objective evidence of breast tumor size ≥1 cm. * 4\. Be able to comply with study procedures to collect the clinical medical information, blood sample, fresh tumor tissue, and 12 sections of paraffin embedded tumor tissue. * 5\. Be able to sign an informed consent. Exclusion Criteria: * 1\. Have histologically confirmed ductal carcinoma in situ (DCIS). * 2\. Stage I, II or III breast cancer patients who have received neoadjuvant treatments, including chemotherapy, hormonal therapy, or targeted therapy. * 3\. Stage IV or metastatic breast cancer patients who have received chemotherapy.
References
Publications (0)
Data not yet available